Preventive Physiotherapy Intervention in Elderly People With Sarcopenia

November 13, 2018 updated by: Maria dels Angels Cebria i Iranzo, PT, PhD, University of Valencia

Effects and Costs of Preventive Physiotherapy Intervention in Institutionalized Elderly People With Sarcopenia: A Randomized Controlled Trial

This study evaluates two strength training protocols (one in peripheral muscles and one in inspiratory muscles) in the improvement of skeletal muscle mass and function in institutionalized elderly with sarcopenia. Participants will be assigned randomly in a control or one of both experimental groups.

Study Overview

Detailed Description

Sarcopenia is a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength with a risk of adverse outcomes such as physical disability, poor quality of life and death (Goodpaster et al, 2006; Delmonico et al, 2007). The contributing factors are those related to aging process, non-optimal diet, bed rest or sedentary lifestyle, chronic diseases and certain drug treatments. Most of these factors are present in the older population with comorbidity, frequently institutionalized to receive a professional long-term care.

Since the European Working Group on Sarcopenia in Older People (Cruz-Jentoft et al, 2010) recommends using the presence of both low muscle mass and low muscle function (strength and/or physical performance) for the diagnosis of sarcopenia, interventions should be focused in both criteria. The aim of this study is to prevent loss of skeletal muscle mass and strength in institutionalized elderly with sarcopenia.

To this purpose, the investigators study undertakes two physiotherapy interventions to preventing/treating Sarcopenia, namely, maintenance of muscle mass and improvement of strength in peripheral and respiratory muscles. Both interventions are common in the following features: supervision, duration, frequency and intensity of the training program.

The primary outcomes are those related to muscle mass and strength. Secondary outcomes will be related to muscle function (muscle endurance and/or physical performance), costs and health status (number of falls and fractures, exacerbations of chronic diseases, hospitalizations and deaths during the year after concluding the physiotherapy interventions).

Study Type

Interventional

Enrollment (Actual)

91

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Valencia, Spain, 46015
        • Grupo Gero Residencias "La Saleta"

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • People aged > 65 years
  • Sarcopenia diagnosis (Tyrovolas et al., 2015)
  • Medically stable at least 2 months before the study

Exclusion Criteria:

  • Cardiorespiratory, muscular, neurological, or neuromuscular disease that could interfere in the proper performance of assessment and/or training protocols.
  • Endocrine and metabolic disorders that might have had an effect on muscle mass.
  • Severe disorder of hydration status that could interfere in Bioelectrical Impedance Analysis (Rubbieri et al., 2014).
  • A terminal disease diagnosis.
  • Mini-Mental State Examination Index ≤ 20 score.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control group
Usual care
Experimental: Respiratory training group

Participants will breathe against a load ≥ 50% of their baseline MIP, after which loads will increase according to the participant's tolerance across the remaining training period, using a Borg scale rating of 4 to 6 on perceived exertion as an indicator of adequate training intensity.

Intervention: Inspiratory Muscle training (12-weeks)

Supervised interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. This protocol is published as a practical guide for clinicians by Hill et al (2010).

The sessions will take place 3 times per week over a twelve-week period for a total of 36 sessions. All participants will be familiarized with the breathing exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of baseline MIP. Participants remain seated in groups of 8 to 10.

Other Names:
  • Threshold IMT (Respironics Health Inc. Cedar Grove, NJ, USA)
Experimental: Peripheral training group

Participants will load ≥ 50% of their maximum muscle force (Kg), after which load will increase according to the participant's tolerance across the remaining training period, using a Borg scale rating of 4 to 6 on perceived exertion as an indicator of adequate training intensity.

Intervention: Peripheral muscle training (12-weeks)

The supervised training program consists of one cycle of 10 exercises, 12 repetitions each one. The main peripheral muscles to be trained will be those recommended by Cruz-Jentoft et al (2011): brachial biceps and triceps, pectorals, deltoid, hand flexors and extensors, spine extensor muscles, psoas-iliac, quadriceps femoris and sural triceps.

The sessions will take place 3 times per week over a twelve-week period for a total of 36 sessions. All participants were familiarized with the force exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of maximum muscle force. Participants remain seated in groups of 8 to 10.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Muscle mass
Time Frame: The groups will be assessed at baseline (pre-intervention) and at the end of the training program (week 12, post-intervention).
Bioimpedance analysis (BIA) estimates the volume of fat and lean body mass. The test itself is inexpensive, easy to use, readily reproducible and appropriate for both ambulatory and bedridden patients. Reference: J Aging Phys Act 2015;23(4):597-606. Korean J Intern Med 2016;31:643-650.
The groups will be assessed at baseline (pre-intervention) and at the end of the training program (week 12, post-intervention).
Change in Maximum Respiratory Pressures (MIP and MEP)
Time Frame: The groups will be assessed at baseline (pre-intervention) and at the end of the training program (week 12, post-intervention).
MIP and MEP are probably the most frequently reported non-invasive estimates of respiratory muscle strength. Ever since Black and Hyatt (1969) reported this technique it has been widely used in patients, healthy control subjects across all ages, and athletes. Pressure is recorded at the mouth during a quasi-static short (few seconds) maximal breathing. Reference: Am J Respir Crit Care Med. 2002;166:531-535.
The groups will be assessed at baseline (pre-intervention) and at the end of the training program (week 12, post-intervention).
Change in Handgrip strength
Time Frame: The groups will be assessed at baseline (pre-intervention) and at the end of the training program (week 12, post-intervention).
Isometric hand grip strength is strongly related with lower extremity muscle power, knee extension torque and calf cross-sectional muscle area. In practice, there is also a linear relationship between baseline handgrip strength and incident disability for activities of daily living. Reference: Age and Aging. 2010;39:412-423.
The groups will be assessed at baseline (pre-intervention) and at the end of the training program (week 12, post-intervention).
Change in peripheral muscle strength
Time Frame: The groups will be assessed at baseline (pre-intervention) and at the end of the training program (week 12, post-intervention).
Maximal isometric muscle strength (Kg) was assessed for knee extension (Quadriceps femoris) and elbow flexion (Biceps brachii). Reference: J Am Geriatr Soc 2002; 50: 461-7.
The groups will be assessed at baseline (pre-intervention) and at the end of the training program (week 12, post-intervention).

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Maximal Voluntary Ventilation (MVV)
Time Frame: The groups will be assessed at baseline (pre-intervention) and at the end of the training program (week 12, post-intervention).
This ventilatory test is a non-invasive technique and is a measure of both inspiratory and expiratory muscle endurance. The MVV is the largest volume that can be breathed in and out of the lungs during a 12 -15 second interval with maximal voluntary effort. Reference: Am J Respir Crit Care Med. 2002;166:562-564.
The groups will be assessed at baseline (pre-intervention) and at the end of the training program (week 12, post-intervention).
Change in Time performed to walk 10 m distance (10mWT).
Time Frame: The groups will be assessed at baseline (pre-intervention) and at the end of the training program (week 12, post-intervention).
The 10-Meter Walk Test (10mWT) is a measure of gait speed (measurement of physical performance). The walking course consist of 14 m in a hallway: a 2 m warm-up, 10 m use for the speed measurement, and 2 m for slowing down to stop. Participants can use the assistive device (eg, cane, walker) or orthotic device (eg, ankle-foot orthosis) that they use "most often" (if any) at each time point. Reference: Phys Ther. 2010;90(2):196-208.
The groups will be assessed at baseline (pre-intervention) and at the end of the training program (week 12, post-intervention).

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Falls and fractures
Time Frame: Intervention costs will be recorded from the time zero to 12-weeks.
Number of falls and resulting fractures will be checked from the medical history of participants.
Intervention costs will be recorded from the time zero to 12-weeks.
Intervention costs
Time Frame: Intervention costs will be recorded from the time zero to 12-weeks.
Intervention costs related to staff (supervision of training programs), consumables (Threshold IMT and weights-ballasts) and capital for intervention will be calculate in 2014 €. Reference: Rev Esp Geriatr Gerontol. 2014;49:203-209.
Intervention costs will be recorded from the time zero to 12-weeks.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Maria A Cebrià i Iranzo, PT, PhD, University of Valencia
  • Study Chair: María J Ponce Darós, PT, PhD, University of Valencia

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2014

Primary Completion (Actual)

March 1, 2016

Study Completion (Actual)

June 1, 2016

Study Registration Dates

First Submitted

April 16, 2014

First Submitted That Met QC Criteria

April 22, 2014

First Posted (Estimate)

April 23, 2014

Study Record Updates

Last Update Posted (Actual)

November 15, 2018

Last Update Submitted That Met QC Criteria

November 13, 2018

Last Verified

July 1, 2017

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

Results are published in a J Aging Phys Act. 2018. 1;26(4):637-646.

IPD Sharing Time Frame

2018 Oct

IPD Sharing Access Criteria

doi: 10.1123/japa.2017-0268

IPD Sharing Supporting Information Type

  • Clinical Study Report (CSR)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sarcopenia

Clinical Trials on Inspiratory Muscle Training (IMT).

3
Subscribe